Effects Of Progesterone Therapy On Serum Sclerostin Levels In Healthy Menopausal Women: A 3-Month Ra

A 3-month randomized, placebo-controlled clinical trial was designed to evaluate the impacts of progesterone therapy on serum sclerostin levels in healthy menopausal women. Researchers derived sclerostin levels for an ethics-approved post hoc analysis. They assessed fasting sclerostin in all remaining sera from a previous 12-week randomized controlled trial (RCT) of oral micronized progesterone (progesterone) for menopausal (> 1 year after last flow) vasomotor symptoms (VMS). In this study, women in the RCT took 300 mg progesterone at bedtime or placebo (1:1) in a trial exhibiting progesterone significantly reduced VMS. This study’s findings demonstrate that physiological oral micronized progesterone did not stimulate nor suppress serum sclerostin levels based on post hoc analysis of RCT data. Exploratory outcomes, nevertheless, exhibited sclerostin negatively associated with CVD risk and quality of life.

​

Source